Institute of
bioorganic chemistry

Scientists from the Laboratory of biomolecular modeling IBCh authors contributed to a study of a single-pass membrane receptor FIBCD1 and its role in neurodevelopmental disorders. This receptor has a high expression level in the brain and its function in the central nervous system was unknown before. It was shown that FIBCD1 as an endocytic receptor for sulfated glycosaminoglycans in the brain extracellular matrix and a novel gene associated with neurodevelopmental disorders, revealing a critical role in nervous system plasticity. Structural aspects of the study includes an original ligand docking framework of the Laboratory, molecular dynamic simulations, homology modeling and AlphaFold structure prediction. The study is published in EMBO Molecular Medicine (IF 14.2)

Vaccination protects against COVID-19 via the spike protein receptor-binding domain (RBD)-specific antibody formation, but it also affects the innate immunity. In the present study, the team of scientists from the Laboratory of cell interactions IBCh RAS in collaboration with the colleagues from MIPT demonstrated that RBD-coated 100 nm particles induced neutrophil activation after the application to the airways of mice with in advance induced RBD-specific antibodies. In these mice, the portion of mature neutrophils was elevated in the circulating neutrophil population. These neutrophils demonstrated decreased ability of neutrophil extracellular traps (NETs) formation compared to the neutrophils from control mice. Thus, the induction of RBD-specific antibodies stimulates the activation of mature neutrophils that react to RBD-coated particles without triggering excessive inflammation. The study was supported RFBR 20-04-60311 and published in the International Journal of Molecular Sciences.

Both ganglioside GD2-specific immunotherapy and antibody-drug conjugates (ADCs), as a class of targeted drugs, have demonstrated clinical success as solid tumor therapies in recent years, yet practically no research has been carried out on ADCs directed to ganglioside GD2. In a new study, scientists from the Department of immunology at IBCh RAS in collaboration with colleagues from other Russian institutes for the first time show that clinically relevant anti-GD2 antibody-drug conjugates manifest potent and highly selective cytotoxicity in a wide panel of cell lines with varying GD2 expression and strongly inhibit tumor growth in mouse models of GD2-positive solid cancer. The work is published in the Journal for ImmunoTherapy of Cancer. Learn more

A team of scientists from the Laboratory of polymers for biology IBCh RAS has developed an original formation method of transparent thermoreversible chitosan alcogels with controlled mechanical strength by cooling chitosan/H₂O/ethanol ternary systems down to temperatures higher than their freezing points. Non-swelling (at pH ≥ 5,5) structures of complex shape were produced by processing preformed alcogels with base solutions. In collaboration with colleagues from FSRC “Crystallography and photonics” RAS we demonstrated nanofibrous structure of the produced gels and revealed that the developed method can be easily applied for such techniques as pressure casting and 3D printing. The results of in vitro and in vivo experiments showed lack of pronounced cytotoxicity and demonstrated biocompatibility with living tissues. The work was published in the International Journal of Biological Macromolecules.

Scientists from the Laboratory of biosynthesis of physiologically active compounds and Laboratory of biopharmaceutical technologies (IBCH RAS) and EIMB RAS synthesized a new series of flexible 5′-norcarbocyclic aza/deaza-purine nucleoside analogs and evaluated as potential inhibitors of E. coli purine nucleoside phosphorylase. The synthesized compounds were evaluated as potential inhibitors of E. coli purine nucleoside phosphorylase. Three analogs were found to be noncompetitive inhibitors with inhibition constants of 14–24mM. From the data obtained, it can be assumed that the new 5′-norcarbocyclic nucleoside analogs interact with the active site of the PNP like natural heterocyclic bases. But at the same time the presence of a cyclopentyl moiety with 2′ and 3′ hydroxyls is necessary for the inhibitory properties, since compounds without those groups did not exhibit an inhibitory effect under the experimental conditions. The results are published in the Frontiers in Chemistry. Learn more